| ID Source | ID |
|---|---|
| PubMed CID | 20140 |
| CHEMBL ID | 1075733 |
| CHEBI ID | 134767 |
| SCHEMBL ID | 387435 |
| MeSH ID | M0131513 |
| Synonym |
|---|
| valmetamide |
| axiquel |
| 4171-13-5 |
| nsc-32363 |
| nsc-34092 |
| nsc34092 |
| pentanamide, 2-ethyl-3-methyl- |
| wln: zvy2&y2&1 |
| ethylmethyl valeramide |
| mi 181 |
| valeramide, 2-ethyl-3-methyl- |
| 2-ethyl-3-methylvaleramide |
| mcn-x-181 |
| valnoctamide |
| nirvanil |
| valmethamide |
| nsc32363 |
| axiquel (tn) |
| valnoctamide (usan/inn) |
| D02717 |
| 2-ethyl-3-methyl-pentanamide |
| 2-ethyl-3-methylpentanamide |
| val.meta.mide |
| valnoctamidum [inn-latin] |
| brn 1749434 |
| valoctamidum |
| einecs 224-033-7 |
| amid kyseliny 2-ethyl-3-methylvalerove [czech] |
| alpha-ethyl-beta-methyl-valeramide |
| nsc 34092 |
| valnoctamide [usan:inn] |
| valnoctamida [inn-spanish] |
| nsc 32363 |
| CHEBI:134767 |
| CHEMBL1075733 |
| AKOS006240025 |
| 3o25nrx9yg , |
| unii-3o25nrx9yg |
| valnoctamida |
| amid kyseliny 2-ethyl-3-methylvalerove |
| 3-02-00-00812 (beilstein handbook reference) |
| valnoctamidum |
| FT-0675768 |
| valnoctamide [mi] |
| valnoctamide [who-dd] |
| valnoctamide [usan] |
| valnoctamide [mart.] |
| valnoctamide [inn] |
| 2-ethyl-3-methylpentamid |
| SCHEMBL387435 |
| QRCJOCOSPZMDJY-UHFFFAOYSA-N |
| sr-01000945257 |
| SR-01000945257-1 |
| valnoctamide, >=98% (nmr) |
| DB13099 |
| DTXSID40863333 |
| Z1198155509 |
| leadphosphite,dibasic |
| Q410468 |
| HY-121877 |
| CS-0083592 |
| MS-22822 |
| EN300-178382 |
Valproic acid derivative associated with decreased risk for congenital abnormalities in animals. Valnoctamide is an analog of valproate that does not undergo biotransformation to the corresponding free acid.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Valnoctamide is a valproic acid derivative associated with a decreased risk for congenital abnormalities in animals." | ( A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bialer, M; Cirjaliu, D; Davis, JM; Levi, L; Levine, SZ; Matei, V; Sava, C; Shekh-Ahmad, T; Sinita, E; Tiugan, A; Weiser, M; Zamora, D, 2017) | 1.41 |
| "Valnoctamide is an analog of valproate that does not undergo biotransformation to the corresponding free acid." | ( Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Agam, G; Applebaum, J; Belmaker, RH; Bersudsky, Y; Gaiduk, Y; Mishory, A; Podberezsky, A; Sharony, L, 2010) | 2.52 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Valnoctamide has a stereoselective PK with (2S,3S)-VCD exhibiting the lowest clearance and, consequently, a twice-higher plasma exposure than all other stereoisomers." | ( The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Bialer, M; Mawasi, H; McDonough, JH; Shekh-Ahmad, T; Yagen, B, 2015) | 1.39 |
| "Valnoctamide has similar activity as SPD in the soman-induced SE model." | ( The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Bialer, M; Mawasi, H; McDonough, JH; Shekh-Ahmad, T; Yagen, B, 2015) | 1.39 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The liver toxicity of valproic acid (VPA) is an established side effect of this widely used antiepileptic drug, which is extremely problematic for patients with metabolic epilepsy and particularly epilepsy due to mitochondrial dysfunction." | ( Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. Bialer, M; Eisenkraft, A; Elger, CE; Kudin, AP; Kunz, WS; Mawasi, H, 2017) | 0.46 |
Valnoctamide is a CNS-active amide derivative of a chiral isomer of valproic acid. It exhibits enantioselective and diastereoselectivity, an observation that may have important practical implications.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Valnoctamide exhibits enantioselectivity and diastereoselectivity, an observation that may have important practical implications if pharmacodynamic differences between stereoisomers are also found." | ( Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Barel, S; Bialer, M; Perucca, E; Pisani, F; Schurig, V; Soback, S; Yagen, B, 1997) | 2 |
| " We utilized pharmacokinetic considerations in designing various amide derivatives of VPA which are more potent as anticonvulsants than VPA and have the potential to be nonteratogenic and nonhepatotoxic." | ( Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. Bialer, M, 1999) | 0.3 |
| " Consequently, in all three animal species the half-life (t1/2) of (2S,3R)-VCD was not different from the t1/2 of the other three VCD stereoisomers." | ( Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. Bennett, GD; Bialer, M; Blotnik, S; Finnell, RH; Spiegelstein, O; Yagen, B, 2000) | 0.57 |
| " Stereoselectivity was observed in clearance, volume of distribution, and in brain-to-plasma AUC ratio at a dose of 25 mg/kg, but the difference disappeared at higher doses as the clearance of the stereoisomers decreased and their half-life increased." | ( Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Bialer, M; Isoherranen, N; Klein, BD; Roeder, M; Schurig, V; White, HS; Woodhead, JH; Yagen, B, 2003) | 0.56 |
| "The purpose of this study was to evaluate the stereoselective pain relieving (antiallodynic) activity, antiallodynic-anticonvulsant correlation, teratogenicity and pharmacokinetic profile of two stereoisomers of valnoctamide (VCD), a CNS-active amide derivative of a chiral isomer of valproic acid (VPA)." | ( Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Bialer, M; Devor, M; Finnell, RH; Kaufmann, D; Minert, A; Schurig, V; Wlodarczyk, B; Yagen, B, 2010) | 0.77 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Following oral administration, the absolute bioavailability of VCD was 94 +/- 14%, and the terminal half-life was similar to that obtained after iv administration." | ( Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. Bialer, M; Haj-Yehia, A, 1988) | 0.54 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily." | ( Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Barel, S; Bialer, M; Perucca, E; Pisani, F; Schurig, V; Soback, S; Yagen, B, 1997) | 0.84 |
| "Significant decreases in pregnancy weight gain and the number of live fetuses were observed when VPA was administered at the high dose, whereas the percentage of exencephalic fetuses was significantly increased in VPA treated compared with an equivalent VCD dosage group." | ( Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. Bialer, M; Cabrera, RM; Finnell, RH; Lin, YL; Wlodarczyk, BJ, 2019) | 0.74 |
| Class | Description |
|---|---|
| fatty amide | A monocarboxylic acid amide derived from a fatty acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID470102 | Antiallodynic activity in ip dosed rat assessed as protection against spinal nerve ligation-induced neuropathic pain | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
| AID470103 | Antiepileptic activity in ip dosed CF1 mouse assessed as inhibition of maximal electroshock-induced seizures | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
| AID470104 | Ratio of ED50 for antiallodynic activity in rat assessed as protection against spinal nerve ligation-induced neuropathic pain to ED50 for antiepileptic activity in rat by maximal electroshock-induced seizures assay | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (19.15) | 18.7374 |
| 1990's | 8 (17.02) | 18.2507 |
| 2000's | 8 (17.02) | 29.6817 |
| 2010's | 22 (46.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (4.08%) | 5.53% |
| Reviews | 2 (4.08%) | 6.00% |
| Case Studies | 1 (2.04%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 44 (89.80%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||